导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.80% | 1967/4773 |
| 近一周 | -1.62% | 1385/5458 |
| 近一月 | -2.35% | 1477/5421 |
| 近一季 | -2.93% | 1825/5205 |
| 近半年 | -9.73% | 3600/4920 |
| 近一年 | 8.16% | 1354/4361 |
| 近两年 | 60.27% | 1230/2954 |
| 近三年 | 37.61% | 798/2253 |
| 成立以来 | 71.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.48% 513/4961 |
1.20% 3067/5312 |
- - |
- - |
| 2025 | 27.40% 1560/4813 |
0.76% 1774/3635 |
1.70% 2220/4076 |
20.82% 1913/4524 |
2.90% 817/4813 |
| 2024 | 12.26% 1258/3463 |
3.31% 597/2808 |
-0.53% 782/3014 |
9.56% 2687/3129 |
-0.29% 1371/3463 |
| 2023 | -8.53% 1024/2656 |
6.12% 723/2280 |
-4.81% 1292/2385 |
-4.06% 1054/2515 |
-5.62% 1425/2655 |
| 2022 | -21.13% 1011/2207 |
-10.26% 386/1919 |
2.05% 1372/2016 |
-10.59% 429/2113 |
-3.68% 1862/2208 |
| 2021 | 10.19% 439/1822 |
-5.55% 935/1255 |
7.98% 653/1330 |
6.48% 222/1466 |
1.47% 918/1822 |
| 2020 | 30.97% 511/1250 |
-1.77% 236/1028 |
18.35% 341/1067 |
10.17% 577/1164 |
2.26% 1002/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 中邮中证500指数增强C VS. 长安沪深300非周期A(740101) |